LPAR5 as a prospective therapeutic target for treating microvillus inclusion disease
- PMID: 40304314
- PMCID: PMC12113019
- DOI: 10.1080/14728222.2025.2500416
LPAR5 as a prospective therapeutic target for treating microvillus inclusion disease
Keywords: Congenital diarrhea and enteropathy (CODE); enteroid; lysophosphatidic acid; mouse model; small intestine.
Conflict of interest statement
Declaration of interest
I Kaji is a named inventor on a patent application related to this research and owned by the Vanderbilt University. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Similar articles
-
Alterations in cellular metabolic pathway and epithelial cell maturation induced by MYO5B defects are partially reversible by LPAR5 activation.Am J Physiol Gastrointest Liver Physiol. 2024 Dec 1;327(6):G877-G899. doi: 10.1152/ajpgi.00091.2024. Epub 2024 Oct 15. Am J Physiol Gastrointest Liver Physiol. 2024. PMID: 39404772 Free PMC article.
-
Altered cellular metabolic pathway and epithelial cell maturation induced by MYO5B defects are partially reversible by LPAR5 activation.bioRxiv [Preprint]. 2024 Sep 8:2024.09.03.610579. doi: 10.1101/2024.09.03.610579. bioRxiv. 2024. Update in: Am J Physiol Gastrointest Liver Physiol. 2024 Dec 1;327(6):G877-G899. doi: 10.1152/ajpgi.00091.2024. PMID: 39282272 Free PMC article. Updated. Preprint.
-
Expression of lysophosphatidic acid receptor 5 is necessary for the regulation of intestinal Na+/H+ exchanger 3 by lysophosphatidic acid in vivo.Am J Physiol Gastrointest Liver Physiol. 2018 Oct 1;315(4):G433-G442. doi: 10.1152/ajpgi.00130.2018. Epub 2018 May 24. Am J Physiol Gastrointest Liver Physiol. 2018. PMID: 29792531 Free PMC article.
-
Altered MYO5B Function Underlies Microvillus Inclusion Disease: Opportunities for Intervention at a Cellular Level.Cell Mol Gastroenterol Hepatol. 2022;14(3):553-565. doi: 10.1016/j.jcmgh.2022.04.015. Epub 2022 Jun 1. Cell Mol Gastroenterol Hepatol. 2022. PMID: 35660026 Free PMC article. Review.
-
Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer.Pharmacol Ther. 2023 May;245:108414. doi: 10.1016/j.pharmthera.2023.108414. Epub 2023 Apr 13. Pharmacol Ther. 2023. PMID: 37061203 Free PMC article. Review.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources